Introduction {#s1}
============

Diabetes mellitus (DM) is a chronic inflammatory disease that seriously threatens human health, and is affected by the interaction between genetic and environmental factors ([@B44]). DM is caused by a metabolic disorder of the endocrine system, and a long-term illness can lead to tissues and organs damage to the cardiovascular, endocrine, nervous, and urinary systems ([@B12]). Beta cell (β cell) failure plays an important role in the development of type 2 DM (T2DM). The dysregulation of metabolic and inflammatory process caused by the onset of DM contributes to the loss of islet function and impaired insulin secretion of β cells, and then affect the body's immune system, leading to various complications of DM ([@B25]).

Traditional Chinese medicine (TCM) has been used for treating DM for more than 2000 years. Relevant studies have shown that TCM can significantly improve blood sugar and clinical indicators of diabetic patients, and effectively delay the progress of DM. ([@B36]). *Lobelia chinensis* (*L. chinensis* Lour.) is an annual dwarf herb, belonging to the family Campanulaceae, and is widely distributed in East Asian countries including China, Korea, and Japan ([@B42]). Modern pharmacology research indicates that the whole herb of *L. chinensis* contains a variety of alkaloids, which has medicinal functions of clearing heat-toxin, promoting diuresis, and diminishing inflammatory ([@B21]). According to preliminary literature reports, *L. chinensis* contains flavonoids ([@B42]), terpenoids ([@B8]), lignans ([@B33]), alkaloids ([@B20]), and some other active ingredients. Although the active ingredients in *L. chinensis* are known, it is still unclear how the active ingredients act on target proteins and regulate signaling pathways to achieve the pharmacological effects of anti-inflammatory and anti-diabetic.

In order to comprehensively evaluate the pharmacological effects of TCM, network pharmacology has been introduced to explore the molecular mechanism of TCM in recent years ([@B16]; [@B17]). The development of systematic pharmacological studies on the relationship between biological processes and the treatment of TCM has attracted considerable interest. Therefore, by integrating systematic information with the overall characteristics of TCM to achieve a comprehensive analysis, and turning the idea of "one drug, one target and one disease" to multi-target combination ([@B30]). Based on network interaction to study the basic biological knowledge of TCM can provide a deep insight or scientific evidence for the discovery of TCM, and help us to clarify the pharmacological mechanism of active ingredients of TCM at the level of biomolecule ([@B43]). Network pharmacology is gradually becoming a holistic and efficient tool to describe the complex interactions between drugs and biological systems including the human organs, diseases, metabolic pathways, and target proteins from a network perspective([@B47]). Combined with pharmacology and pharmacodynamics, it has been successfully applied to explain the mechanism of TCM at the molecular network level ([@B45]). In this study, we first identified the active ingredients in *L. chinensis* by metabolomics analysis. Based on the pharmacokinetic and pharmacological data of components, we constructed a network pharmacological model of active ingredients, and systematically analyzed the potential anti-diabetes mechanism of active ingredients in *L. chinensis*. The detailed procedures can be seen in [**Figure 1**](#f1){ref-type="fig"}.

![The flowchart of the network pharmacological analysis approach.](fphar-11-00347-g001){#f1}

Materials and Methods {#s2}
=====================

Description of the Study Material {#s2_1}
---------------------------------

*L. chinensis* is a plant, commonly called Chinese lobelia, creeping lobelia, or Banbianlian, is a low-growing, tiny-leaved, herbaceous perennial that typically forms an attractive ground cover rising to only 2--3″ tall but spreading rapidly by creeping decumbent stems to 36″ wide. Creeping stems are clad with narrow, lanceolate, green leaves (to 3/4″ long). Pale pink to white, usually solitary flowers (1 1/4″across) bloom from the leaf axils from July to October. Each lobelia-like flower features two lanceolate to oblanceolate lateral lobes and three more prominent central elliptic lobes in a flattened plane. *L. chinensis* is 1 of the 50 fundamental herbs used in TCM ([**Supplementary Figure 3**](#SM1){ref-type="supplementary-material"}). Voucher specimen accession number NAS00276292 was deposited in Institute of Botany, Jiangsu Province and Chinese Academy of Sciences ([**Supplementary Figure 1**](#SM1){ref-type="supplementary-material"}).

Determination of Active Ingredients From *L. chinensis* {#s2_2}
-------------------------------------------------------

*L. chinensis* was collected in Quanjiao, Anhui Province, and now is preserved in the Institute of Life Sciences, Jiangsu University. The whole plants were dried and ground to a fine powder in an electric grinder. All chemicals and reagents were analytical or HPLC grade. The 60 mg accurately weighted *L. chinensis* powder was transferred to a 2.0-ml Eppendorf tube. Two small steel balls were added to the tube, 360 μl of cold methanol and 40 μl of internal standard (0.3 mg/ml 2-chloro-L-phenylalanine, dissolved in methanol) were added to the tube, and then placed at −80°C for 2 min, ground at 60 Hz for 2 min, and sonicated for 30 min. After that, 200 μl of chloroform was added to the tube and the mixtures were mixed thoroughly at ambient temperature, then 400 μl of water was added. The samples were centrifuged at 12,000*g* for 10 min at 4°C. An aliquot of the 200 μl supernatant was transferred to a glass sampling vial for desiccation at room temperature. Eighty microliters of methoxyamine hydrochloride in pyridine (15 mg/ml) was subsequently added. The resultant mixture was vortexed vigorously for 2 min and incubated at 37°C for 90 min, then 80 μl of BSTFA (with 1% TMCS) and 20 μl n-hexane was added into the mixture, which was vortexed vigorously for 2 min and incubated at 70°C for 60 min. All the samples were placed at ambient temperature for 30 min before gas chromatography--mass spectrometry (GC-MS) analysis. And all the samples were tested in triplicate.

GC-MS Experiments {#s2_3}
-----------------

The derivatized samples were analyzed on an Agilent 7890B gas chromatography system coupled to an Agilent 5977A MSD system (Agilent Technologies Inc., CA, USA). DB-5MS fused-silica capillary columns (30 m × 0.25 mm × 0.25 µm, Agilent J & W Scientific, Folsom, CA, USA) with highly pure helium (purity not less than 99.999%) at a constant ﬂow rate of 1.0 ml/min were utilized to separate the derivatives. The injector temperature was maintained at 260°C. Injection volume was 1 μl, and the split ratio was 10:1. The initial temperature of the column oven was 60°C, ramped to 125°C at a rate of 8°C/min, to 210°C at a rate of 4°C/min, to 270°C at a rate of 5°Cmin, to 305°C at a rate of 10°C/min, and finally held at 305°C for 3 min. The temperature of MS quadrupole and ion source (electron impact) was set to 150°C and 230°C, respectively. The collision energy was 70 eV. Scan mode was Full Scan mode (SCAN) and mass scan range was m/z 50--500.

Chemical Ingredients Database Building and Screening {#s2_4}
----------------------------------------------------

All of the constituent data of *L. chinensis* were obtained from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, <http://lsp.nwu.edu.cn/tcmsp.php>) ([@B31]). The active ingredients obtained from GC-MS and supplemented through a wide-scale text-mining method were input into TCMSP website to screen the chemical ingredients that interact with DM and inflammation. The effective ingredients of *L. chinensis* are mainly filtered by oral bioavailability (OB) and blood--brain barrier (BBB) permeability. OB is one of the most important pharmacokinetic parameters in the characteristics of absorption, distribution, metabolism, and excretion (ADME) characteristics of drugs, indicating the ratio of the oral drug to the oral dosage of the blood circulatory system ([@B10]). The ADME parameter-based virtual screening of the ingredients was utilized to further identify anti-diabetic ingredients using an OB threshold OB ≥ 30% and barrier permeability (BBB) ≥ −0.30 as parameters ([@B37]). Meanwhile, the chemical information of these ingredients (structure, specification name, and CID number) for computational analysis were also collected according to the Pub Chem (<https://pubchem.ncbi.nlm.nih.gov/>) and Drug Bank (<https://www.drugbank.ca/drugs>).

Ingredient--Target Network Construction {#s2_5}
---------------------------------------

In order to identify the corresponding targets of the active ingredients of *L. chinensis*, a method combined with information integration and data mining was implemented. First of all, the active ingredients and interact targets were submitted to Cytoscape 3.2.1 software to construct an ingredient--target network to explore the pharmacological mechanism of the active ingredients of *L. chinensis*. The input data with Excel format file can be seen in the [**Supplementary Tables 3**](#SM2){ref-type="supplementary-material"} **and** [**4**](#SM3){ref-type="supplementary-material"}.

Protein-Protein Interaction Network Construction {#s2_6}
------------------------------------------------

To explain the interaction between target proteins, the target proteins of related ingredients of *L. chinensis* were uploaded to STRING (<http://string-db.org>) online website to obtain the information of protein-protein interaction (PPI). The website generated a score for each protein mutual information. The higher the score, the higher the confidence in the interaction between target proteins. Therefore, we selected high confidence data \>0.7 to ensure the reliability of this analysis. The obtained protein interaction data were imported into Cytoscape 3.2.1 software to construct a PPI protein interaction network.

Gene Ontology and KEGG Enrichment Analysis of Target Proteins {#s2_7}
-------------------------------------------------------------

To elucidate the role of target proteins that interact with the active ingredients of *L. chinensis* in gene function and signaling pathway, the Database for Annotation, Visualization and Integrated Discovery (DAVID, <https://david.ncifcrf.gov/>) v6.8 was used to analyze the Gene Ontology (GO) function and KEGG pathway enrichment of proteins involved in PPI network. The target proteins involved in the cellular components (CC), molecular function (MF), biological process (BP), and the pathways were also described.

Ingredient--Target--Pathway Network Construction {#s2_8}
------------------------------------------------

After getting the interaction information of the active ingredient compounds, target proteins, and the pathways, the "Ingredient--Target--Pathway" network was established by Cystoscope 3.2.1 software. In the network, nodes represent components, targets, and pathways, edges represent the interaction of each other. Then a hypothesized schematic diagram of the target proteins involved in the pathways was drawn. Based on the network model map, the pathway of active ingredients and targets in the disease is initially explored to provide a preliminary theoretical basis for the design of subsequent targeted drugs.

Results {#s3}
=======

GC/MS Determination of Active Ingredients in *L. chinensis* {#s3_1}
-----------------------------------------------------------

To demonstrate the ability of the GC/MS method to accurately separate and identify ingredients, the sample of *L. chinensis* powder was analyzed triple times by GC/MS. The results showed strong signals, high peak capacity, and well reproducibility. The typical total ion current (TIC) was shown in [**Supplementary Figure 2**](#SM1){ref-type="supplementary-material"}. The detected ingredients contained acacetin (4.78 mg/g), norlobelanine (6.05 mg/g), 5-hydroxymethylfurfural (1.26 mg/g), and other bioactive ingredients. The concentration of the active ingredients of *L. chinensis* are shown in [**Table 1**](#T1){ref-type="table"}. A total of 208 chemical ingredients were identified and shown in [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}.

###### 

The concentration of the active ingredients of *Lobelia chinensis*.

  MOL ID      Ingredients                                                                                          Concentration
  ----------- ---------------------------------------------------------------------------------------------------- ---------------
  MOL012231   Leptodactylone                                                                                       23.58 mg/g
  MOL012207   Lobelanidine                                                                                         12.62 mg/g
  MOL001689   Acacetin                                                                                             4.78 mg/g
  MOL012216   Norlobelanine                                                                                        6.05 mg/g
  MOL001999   Scoparone                                                                                            0.13 mg/g
  MOL005928   Isoferulic acid                                                                                      22.77 mg/g
  MOL012209   2-\[(2R,6S)-6-\[(2R)-2-hydroxy-2-phenylethyl\]-1-methylpiperidin-2-yl\]-1-phenylethanone (Lobelin)   46.60 mg/g
  MOL009009   (+)-Medioresinol                                                                                     0.84 mg/g
  MOL004678   Limetin                                                                                              2.51 mg/g
  MOL012208   Lobelanine                                                                                           27.88 mg/g
  MOL002341   Hesperetin                                                                                           3.27 mg/g
  MOL000748   5-Hydroxymethylfurfural (HMF)                                                                        1.26 mg/g
  MOL000103   4-Oxoniobenzoate (PHB)                                                                               5.49 mg/g

Screening of Effective Anti-Diabetic Ingredients in *L. chinensis* {#s3_2}
------------------------------------------------------------------

Early assessment of the ADME properties of candidate active ingredients has become an important process in modern drug discovery. And the correct use of ADME identifies candidates that are more likely to have good pharmacokinetic properties. Currently, OB and BBB are considered as a key parameter in drugs discovery. TCMs are often administered orally, and its OB is determined by body absorption, distribution, and liver metabolism. It is important to identify the active ingredients of medicinal herbs. In this research, OB and BBB indicators were used to screen for *L. chinensis* ingredients with favorable pharmacokinetic properties. Therefore, all chemicals that meet the screening criteria: OB (\> 30%) and BBB (\>-0.3) are considered as candidate ingredients. Twenty-three differentiated ingredients with effective pharmacological activities were identified after screening ADME parameters ([**Table 2**](#T2){ref-type="table"}).

###### 

Ingredients information of *Lobelia chinensis*.

  MOL ID      Name                                                                                                                                                              Molecular Formula   CAS No.      MW (g/mol)   OB%     BBB     DL     HL      Structural Formula
  ----------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- ------------ ------------ ------- ------- ------ ------- ------------------------------
  MOL012207   Lobelanidine                                                                                                                                                      N/A                 552-72-7     339.52       60.53   0.31    0.32   5.78    ![](fphar-11-00347-g007.jpg)
  MOL012208   Lobelanine                                                                                                                                                        C22H25NO2           579-21-5     335.48       54.13   0.46    0.32   31.96   ![](fphar-11-00347-g008.jpg)
  MOL000103   4-Oxoniobenzoate (PHB)                                                                                                                                            C7H6O3              99-96-7      138.13       30.15   0.21    0.03   11.77   ![](fphar-11-00347-g009.jpg)
  MOL012209   2-\[(2R,6S)-6-\[(2R)-2-hydroxy-2-phenylethyl\]-1-methylpiperidin-2-yl\]-1-phenylethanone (Lobelin)                                                                C22H27NO2           90-69-7      337.50       45.53   0.22    0.32   19.19   ![](fphar-11-00347-g010.jpg)
  MOL011678   (3S,8S,9S,10R,13R,14S,17R)-17-\[(1S,4R)-4-ethyl-1,5-dimethylhexyl\]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta\[a\]phenanthren-3-ol   C29H50O             474-58-8     414.79       36.91   1.15    0.75   4.93    ![](fphar-11-00347-g011.jpg)
  MOL012215   Propanol (POL)                                                                                                                                                    C3H8O               71-23-8      60.11        72.69   0.97    0.00   11.62   ![](fphar-11-00347-g012.jpg)
  MOL012216   Norlobelanine                                                                                                                                                     C21H23NO2           6035-31-0    321.45       64.08   0.33    0.30   35.32   ![](fphar-11-00347-g013.jpg)
  MOL012217   Phytenal                                                                                                                                                          N/A                 13754-69-3   294.58       35.22   1.41    0.14   3.96    ![](fphar-11-00347-g014.jpg)
  MOL012221   Trans-10-ethyl-8-methyl-lobelidiol                                                                                                                                N/A                 N/A          229.41       33.93   -0.04   0.07   2.73    ![](fphar-11-00347-g015.jpg)
  MOL012223   Trans-N-methyl-2,6-bis(2-hydroxybutyl)-△3-piperideine                                                                                                             N/A                 N/A          243.44       42.40   -0.19   0.08   4.73    ![](fphar-11-00347-g016.jpg)
  MOL012231   Leptodactylone                                                                                                                                                    C11H10O5            61899-44-3   222.21       37.56   0.22    0.10   2.68    ![](fphar-11-00347-g017.jpg)
  MOL001999   Scoparone                                                                                                                                                         C11H10O4            120-08-1     206.21       74.75   0.46    0.09   0.73    ![](fphar-11-00347-g018.jpg)
  MOL002341   Hesperetin                                                                                                                                                        C16H14O6            520-33-2     302.30       70.31   -0.25   0.27   15.78   ![](fphar-11-00347-g019.jpg)
  MOL004678   Limetin                                                                                                                                                           C11H10O4            487-06-9     206.21       36.63   0.47    0.09   1.33    ![](fphar-11-00347-g020.jpg)
  MOL005928   Isoferulic acid                                                                                                                                                   C10H10O4            537-73-5     194.20       50.83   0.01    0.06   2.45    ![](fphar-11-00347-g021.jpg)
  MOL007170   Cirsiumaldehyde                                                                                                                                                   C12H10O5            7389-38-0    234.22       41.38   0.03    0.11   7.81    ![](fphar-11-00347-g022.jpg)
  MOL000748   5-Hydroxymethylfurfural (HMF)                                                                                                                                     C6H6O3              76330-16-0   126.12       45.07   -0.27   0.02   11.73   ![](fphar-11-00347-g023.jpg)
  MOL009009   (+)-Medioresinol                                                                                                                                                  N/A                 40957-99-1   388.45       87.19   -0.29   0.62   1.39    ![](fphar-11-00347-g024.jpg)
  MOL012232   5-Hydroxy-6,7-dimethoxycoumarin                                                                                                                                   C11H10O5            28449-62-9   222.21       67.31   0.20    0.10   1.83    ![](fphar-11-00347-g025.jpg)
  MOL009653   Cycloeucalenol                                                                                                                                                    N/A                 469-39-6     426.80       39.73   1.04    0.79   5.01    ![](fphar-11-00347-g026.jpg)
  MOL001504   (E,7R,11S)-3,7,11,15-tetramethylhexadec-2-en-1-ol                                                                                                                 C20H40O             150-86-7     296.60       33.82   0.90    0.13   3.46    ![](fphar-11-00347-g027.jpg)
  MOL001689   Acacetin                                                                                                                                                          C16H12O5            480-44-4     284.28       34.97   -0.05   0.24   17.25   ![](fphar-11-00347-g028.jpg)
  MOL004688   Cumic acid                                                                                                                                                        C10H12O2            536-66-3     164.22       45.78   1.10    0.04   -3.13   ![](fphar-11-00347-g029.jpg)

Interactions Analysis of Active Ingredients and Target Proteins {#s3_3}
---------------------------------------------------------------

According to the analysis, the active ingredients of *L. chinensis* have good pharmacological effects on anti-inflammatory and anti-diabetic in a synergistic way. To further study the mechanism of anti-diabetes, it is of paramount important to understand the target proteins on which these ingredients act. With the development of network pharmacology, it provides an effective tool for the study of TCM pharmacology. Using TCMSP, the active ingredients of *L. chinensis* and the target proteins related to inflammation and DM were searched. Cytoscape 3.2.1 was used to analyze the interaction between 23 active ingredients and target proteins. The results are shown in [**Figure 2**](#f2){ref-type="fig"}. The analysis ingredients--targets network consisted a total of 93 nodes and 581 edges, of which 13 are anti-inflammatory and anti-diabetic active ingredients, and the other 80 are target protein nodes. The result shows that MOL001689 (acacetin), MOL012216 (norlobelanine), MOL000748 (5-hydroxymethylfurfural) have more target proteins play a key role in the interaction network, which may be the key ingredients or target proteins that play an anti-inflammation and anti-diabetic role in *L. chinensis*. [**Supplementary Table 2**](#SM1){ref-type="supplementary-material"} lists the ingredients and the related target proteins. Based on the number of ingredients--targets relationships, the number of target proteins acting on average per ingredients is about 6.15. These results indicate that muti-ingredients muti-targets interactions occur in *L. chinensis*.

![*Lobelia chinensis* ingredients--target interaction network. The pink triangle represent the 13 bioactive ingredients, and the blue circle represent the 80 target proteins.](fphar-11-00347-g002){#f2}

Construction and Analysis of Target Proteins PPI Network {#s3_4}
--------------------------------------------------------

The target proteins that act with its corresponding ingredients were submitted to STRING version 10.5 (<http://string-db.org/>) for PPI network construction, and high confidence of protein interaction data with a score \>0.7 was selected ([**Figure 3**](#f3){ref-type="fig"}). The results include a total of 75 nodes, 107edges, of which nodes represent the target proteins and the edges represent the interactions between the proteins. In this network interaction, the larger the degree, the stronger relationship between the proteins corresponding to the node in this network, which indicates that the target proteins play a key role in the whole interaction network, which is the important target protein. [**Figure 3**](#f3){ref-type="fig"} shows that PIK3CA, PDPK1, AKT1, and TNF are centrally located in the PPI network, indicating that these proteins are involved in the pathogenesis of DM and inflammation.

![Protein--protein interaction (PPI) network analysis.](fphar-11-00347-g003){#f3}

GO Analysis of Target Proteins {#s3_5}
------------------------------

GO enrichment analysis of target proteins that act with its corresponding ingredients was performed by DAVID. The top 10 significantly enriched terms in BP, MF, and CC categories were selected, according to P \< 0.05, P-values were corrected using the Benjamini--Hochberg procedure. As shown in [**Figure 4**](#f4){ref-type="fig"}, BP (198 records), MF (40 records), and CC (32 records) accounted for 71.74%, 16.67%, and 11.59%, respectively. In the BP category, the target proteins were mainly involved in inflammatory response, participate in leukocyte migration, and glucose metabolic process. In the MF category, the target proteins were mainly involved in protein homodimerization activity and ATP binding. In the CC category, the target proteins were classified into plasma membrane and cell surface. The GO enrichment analysis results showed that the active ingredients of *L. chinensis* could bind kinase in cell membrane and plasma membrane in the process of inflammation, so as to exert anti-inflammatory and anti-diabetic potential.

![Gene Ontology (GO) enrichment analysis of the target proteins. Biological process (green), molecular function (purple), and cellular component (blue) accounted for 71.47%, 16.67%, and 11.59%, respectively.](fphar-11-00347-g004){#f4}

KEGG Classification of Target Proteins {#s3_6}
--------------------------------------

To further clarify the relationship between target proteins and the pathways, we constructed a target--pathway interaction network using the data extracted from DAVID database ([**Figure 5A**](#f5){ref-type="fig"}), and the top 20 pathways involving 33 target proteins were screened according to the KEGG analysis with BH-corrected P-values \< 0.05 ([**Figure 5B**](#f5){ref-type="fig"}). The results showed that these target proteins were mainly involved in insulin resistance, sphingolipid signaling pathway, regulation of lipolysis in adipolysis, NF-kappa B signaling pathway, MAPK signaling pathway, PI3K--AKT signaling pathway, and so on. The target proteins involved in insulin resistance included RAC-alpha serine/threonine-protein kinase (AKT1), carnitine palmitoyltransferase 1B (CPT1B), glycogen synthase kinase 3 beta (GSK3B), inhibitor of nuclear factor kappa B kinase subunit beta (IKBKB), INSR, mitogen-activated protein kinase 9 (MAPK9), nitric oxide synthase 3 (NOS3), phosphoinositide-dependent kinase-1 (PDPK1), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA), protein kinase C beta (PRKCB), glycogen phosphorylase (PYGL), tumor necrosis factor (TNF), and tumor necrosis factor receptor superfamily member 1A (TNFRSF1A); the target proteins involved in sphingolipid signaling pathway were adenosine A1 receptor (ADORA1), AKT1, mitogen-activated protein kinase 14 (MAPK14), MAPK9, NOS3, PDPK1, PIK3CA, phospholipase D1 (PLD1), protein kinase C beta (PRKCB), TNF, and TNFRSF1A; the target proteins involved in MAPK signaling pathway were AKT1, insulin-like growth factor 1 receptor (IGF1R), IKBKB, INSR, interleukin-1 receptor-associated kinase 4 (IRAK4), mast/stem cell growth factor receptor Kit (KIT), MAPK14, MAPK9, phospholipase A2 group IVA (PLA2G4A), PRKCB, angiopoietin-1 receptor (TEK), TNF, and TNFRSF1A. Therefore, there are multiple target proteins in one pathway, and the same target protein exists in multiple pathways. Essentially, a pathway involving multiple target proteins is more important than the interaction between one target protein and multiple pathways. These results suggest that the effective pharmacological active ingredients in *L. chinensis* may act on these signaling pathways to alleviate inflammation, including some chronic inflammation, such as type 2 diabetes and other diseases.

![Targets--pathway interaction analysis **(A)** and KEGG analysis of target proteins **(B)**. The red ellipse represent the target proteins, and the green diamond represent the pathways.](fphar-11-00347-g005){#f5}

Network Analysis of Target Proteins Involved in Signaling Pathways {#s3_7}
------------------------------------------------------------------

As an important part of systemic pharmacology, signaling pathways can link receptor--ligand interactions with pharmacodynamics pathways. All target proteins interacting with the active ingredients of *L. chinensis* were located in the top 20 KEGG pathways and then generated a target--pathway signaling network. Among them, there are lots of target proteins involved in the PI3K--AKT signaling pathway, insulin signaling pathway, and TNF signaling pathway, which play an explicit role in maintaining insulin secretion, glucose homeostasis, and inflammation ([@B35]). TNF is associated with a variety of inflammatory, infectious and malignant diseases ([@B5]). In addition, the vascular endothelial growth factor signaling pathway that involving many target proteins, such as INSR, NOS3, PTGS2, and vascular endothelial growth factor A (VEGFA), plays a key regulatory role in diabetic retinopathy ([@B1]). VEGF can cause injury of vascular endothelial cells (ECs), inflammation, and oxidative stress, which can lead to an abnormal metabolism of blood glucose caused by diabetes, and also cause the insulin secretion from islet cells due to elevation of blood glucose, that aggravates the symptoms of insulin resistance ([@B46]). mTOR is a serine/threonine-protein kinase whose signal transduction regulates protein synthesis and cell growth, especially hypertrophy. Therefore, activation of the mTOR signaling pathway is a potential reason for early renal hypertrophy in DM ([@B32]). Interestingly, after network construction, we also found that active ingredients can play a therapeutic role in type 2 diabetes by activating the VEGFA to regulate the expression of PI3R1 and decreasing insulin resistance. As shown in [**Figure 6**](#f6){ref-type="fig"}, the anti-inflammatory and anti-diabetic active ingredients present in *L. chinensis*, which can synergize with multiple target proteins in these pathways to form a multi-ingredients-multi-targets-multi-pathways mechanism.

![Distribution of the target proteins of *Lobelia chinensis* on the predicted pathway. The orange nodes are potential target proteins of *L. chinensis*, while the blue nodes are relevant targets in the pathway.](fphar-11-00347-g006){#f6}

Discussion {#s4}
==========

Medicinal plants have a long history in the treatment of chronic inflammatory diseases such as DM and various complications. In the pharmacological study of active ingredients, research methods based on network interaction are expected to highlight the understanding of drug action across multiple layers of information. The network model of active ingredients and target proteins is an important way to characterize the pharmacological mechanism of active ingredients, which can provide a theoretical basis for future drug development and design ([@B4]). The research ideas of network pharmacology provide a unique and innovative way for the study of active ingredients in TCM, in order to understand the mechanism of the multi-ingredients-multi-targets mode of TCM ([@B13]).

In this study, 208 metabolites of active ingredients in *L. chinensis* were determined by GC/MS metabonomics analysis. Among them, 23 active ingredients such as lobelanidine, 5-hydroxymethylfural, acacetin, and hesperetin possess the pharmacological activities ([**Table 2**](#T2){ref-type="table"}), of which 13 ingredients have anti-inflammatory and anti-diabetic effects ([**Figure 2**](#f2){ref-type="fig"}). Subsequently, according to the analysis of network pharmacology, we found that these ingredient compounds which have therapeutic effects on inflammation and diabetes-related symptoms can treat or alleviate the symptoms of inflammation and diabetes, through the role of related target proteins in metabolic pathways caused by the occurrence of diseases. GO and KEGG analysis results showed that the target proteins involved in main pathways were inflammation, non-insulin dependent pathway, MAPK signaling pathway, PI3K--AKT signaling pathway, TNF signaling pathway, and DM signaling pathway ([**Figure 5**](#f5){ref-type="fig"}). The systematic pharmacological analysis showed that the active ingredients of 5-hydroxymethylfural and acacetin in *L. chinensis* could stimulate insulin secretion, improve insulin resistance, and promote glucose utilization by acting on GSK3B, MAPK, INR, and dipeptidyl peptidase-4 (DPP4). Meanwhile, they could also regulate inflammatory cytokines, promote endocrine and metabolism, and achieve the therapeutic effect in the treatment of diabetes.

GSK3B is a serine-threonine kinase in glycogen synthase subfamily, and it is also a negative regulator of glycometabolism balance that participates in energy metabolism, inflammatory response, endoplasmic reticulum stress, mitochondrial dysfunction, and apoptotic pathway ([@B23]). Selective inhibition of GSK3B in insulin resistance pathway can improve insulin-stimulated glucose transport activity, which may be due to enhanced insulin signal transduction and GLUT-4 translocation ([@B15]). Therefore, inhibition of GSK3B may have the potential to treat DM and insulin resistance. DPP4 is capable of rapidly degrading endogenous GLP-1, which plays a crucial role in glucose metabolism ([@B2]). At present, GLP-1 is the only known protein to reduce blood glucose levels by increasing insulin secretion ([@B24]). The hypoglycemic mechanism of two diabetic drugs such as sitagliptin and vildagliptin is also based on DPP4 inhibitors ([@B19]; [@B11]). Therefore, it is important to evaluate the inhibitory effect of active ingredients of *L. chinensis* on DPP-4.

According to the results of pathway analysis, mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK, may also play a crucial role in regulating diabetes and inflammation through the MAPK signaling pathway. The MAPKs are extracellular signal-regulated protein kinases, increasing cellular proliferation and involving in the cell survival regulation ([@B7]). MAPK can also be inactivated by protein phosphatases, which counteract many kinase-driven intracellular signaling pathways through dephosphorylating key proteins ([@B29]). The liver is the main important organ to control metabolism in the human body ([@B14]). MAPKs can regulate inflammatory response along with a wide range of cellular processes including cell metabolism, proliferation, motility, apoptosis, survival, differentiation, and survival in physiological and pathological processes ([@B22]). Previous studies have shown that p38 MAPK controls cellular responses to cytokines and stress ([@B48]). Thus, MAPK p38 inhibitors inhibit the production of many proinflammatory cytokines, including IL-1β and TNF-α, and inducible nitric oxide synthase (iNOS) ([@B34]). These findings further confirm that the pharmacological activation of MAPK may be mediated by signal transduction, metabolism, and gene expression, while changes in liver metabolism may lead to the occurrence of insulin resistance, type 2 diabetes, and obesity. Therefore, we think that MAPK may be associated with metabolic diseases, which also provides a new strategy for the treatment of metabolic diseases such as type 2 diabetes and obesity.

Additionally, TNF signaling pathway can induce multiple cascade reactions, including activation of the transcription factor NF-kappa B and programmed cell death ([@B38]). TNF activates the pro-inflammatory function of vascular ECs by binding to cytokines such as TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR expressed on the cell surface and is a potent pyrogen ([@B40]). It is mainly secreted by macrophages and can induce cell death in some cancer cell lines ([@B39]). Previous researches on TNF signaling have indicated that TNF signaling pathway is a negative feedback mechanism, and the activation of NF-kappa B inhibits the signal of cell death ([@B13]). Mavrogonatou and Ji *et al*. have shown that TNF-alpha is an inflammatory mediator, and its overexpression can lead to the rapid activation of p38MAPK under the external or internal stimulation, which promotes the production of IL-6 and induces the body's inflammatory response ([@B18]; [@B27]).

T2DM is caused by insulin resistance and loss of islet beta-cell function. Insulin signaling occurs through the INSR, which is selectively spliced into two isomers: INSR-A and INSR-B ([@B3]). Malakar *et al*. showed that insulin could regulate selective splicing of INSR through Ras-MAPK/ERK signaling pathway and that INSR-B had a protective effect in β cells, while the expression of INSR-A made β cells sensitive to programmed cell death ([@B26]). Previous studies have also shown that insulin signal transduction pathway plays a crucial role in the pathogenesis of diabetes, which is of great significance for the study of insulin signal transduction in type 2 diabetes ([@B13]). Insulin binding to INSR on cell membranes will induce signal transduction, and the insulin receptor substrate (IRS) plays a key role in insulin signaling system ([@B6]). It mediates multidirectional cell signal transduction effects such as IRS and insulin-like growth factor (IGF), thereby exercising the connection and functional regulation with other cytokines ([@B28]).

This enrichment pathway analysis result indicates that insulins can bind to INSR on the cell membrane, and affect the occurrence of diabetes and inflammation through PI3K--AKT signal transduction pathway. After release of insulin into the blood, insulin could bind to insulin receptor (INSR) on the surface of liver cell membrane and then activates insulin receptor phosphorylates tyrosine site of IRS-1/2, regulating the PI3K/AKT signal pathway, of which IRS2 is the main target in the insulin metabolism effects in liver ([@B41]). The activated PI3K can catalyze 4, 5-2 phosphatidyl inositol phosphate (PIP2) and generate PIP3, which may act the second messenger to activate AKT, and the activated AKT has an effect on the biological metabolism by regulating downstream molecules ([@B9]). Therefore, any abnormality in the PI3K--AKT signaling pathway will affect insulin signal transduction, thereby promoting the occurrence and development of insulin resistance and type 2 diabetes.

In summary, the pathogenesis of DM is more complex, and the signal pathways are cross-linked and mutually modulated, presenting a multi-pathway and multi-target pattern. The active ingredients of *L. chinensis* can regulate target proteins involved in signal pathways and play a role in stabilizing signal pathway, revealing the multi-ingredient--multi-target--multi-pathway action mode of TCM. Deep analysis of anti-diabetic and anti-inflammatory pharmacological effects of *L. chinensis*, as well as the target and pathway acting with the active ingredients still need to be further validated.
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